Literature DB >> 29192363

Quantitative and Visual Assessments toward Potential Sub-mSv or Ultrafast FDG PET Using High-Sensitivity TOF PET in PET/MRI.

Spencer C Behr1, Emma Bahroos2, Randall A Hawkins1, Lorenzo Nardo3, Vahid Ravanfar1, Emily V Capbarat1, Youngho Seo1,4.   

Abstract

PURPOSE: Newer high-performance time-of-flight (TOF) positron emission tomography (PET) systems have the capability to preserve diagnostic image quality with low count density, while maintaining a high raw photon detection sensitivity that would allow for a reduction in injected dose or rapid data acquisition. To assess this, we performed quantitative and visual assessments of the PET images acquired using a highly sensitive (23.3 cps/kBq) large field of view (25-cm axial) silicon photomultiplier (SiPM)-based TOF PET (400-ps timing resolution) integrated with 3 T-MRI in comparison to PET images acquired on non-TOF PET/x-ray computed tomography (CT) systems. PROCEDURES: Whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET/CT was acquired for 15 patients followed by whole body PET/magnetic resonance imaging (MRI) with an average injected dose of 325 ± 84 MBq. The PET list mode data from PET/MRI were reconstructed using full datasets (4 min/bed) and reduced datasets (2, 1, 0.5, and 0.25 min/bed). Qualitative assessment between PET/CT and PET/MR images were made. A Likert-type scale between 1 and 5, 1 for non-diagnostic, 3 equivalent to PET/CT, and 5 superior quality, was used. Maximum and mean standardized uptake values (SUVmax and SUVmean) of normal tissues and lesions detected were measured and compared.
RESULTS: Mean visual assessment scores were 3.54 ± 0.32, 3.62 ± 0.38, and 3.69 ± 0.35 for the brain and 3.05 ± 0.49, 3.71 ± 0.45, and 4.14 ± 0.44 for the whole-body maximum intensity projections (MIPs) for 1, 2, and 4 min/bed PET/MR images, respectively. The SUVmean values for normal tissues were lower and statistically significant for images acquired at 4, 2, 1, 0.5, and 0.25 min/bed on the PET/MR, with values of - 18 ± 28 % (p < 0.001), - 16 ± 29 % (p = 0.001), - 16 ± 31 % (p = 0.002), - 14 ± 35 % (p < 0.001), and - 13 ± 34 % (p = 0.002), respectively. SUVmax and SUVpeak values of all lesions were higher and statistically significant (p < 0.05) for 4, 2, 1, 0.50, and 0.25 min/bed PET/MR datasets.
CONCLUSION: High-sensitivity TOF PET showed comparable but still better visual image quality even at a much reduced activity in comparison to lower-sensitivity non-TOF PET. Our data translates to a seven times reduction in either injection dose for the same time or total scan time for the same injected dose. This "ultra-sensitivity" PET system provides a path to clinically acceptable extremely low-dose FDG PET studies (e.g., sub 1 mCi injection or sub-mSv effective dose) or PET studies as short as 1 min/bed (e.g., 6 min of total scan time) to cover whole body without compromising diagnostic performance.

Entities:  

Keywords:  High-sensitivity; PET; PET/CT; PET/MRI; Sub-mSv; TOF; Timing resolution; Ultrafast

Mesh:

Substances:

Year:  2018        PMID: 29192363     DOI: 10.1007/s11307-017-1145-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  29 in total

1.  Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard.

Authors:  Marco Brambilla; Chiara Secco; Marco Dominietto; Roberta Matheoud; Gianmauro Sacchetti; Eugenio Inglese
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

2.  Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.

Authors:  Dominique Delbeke; R Edward Coleman; Milton J Guiberteau; Manuel L Brown; Henry D Royal; Barry A Siegel; David W Townsend; Lincoln L Berland; J Anthony Parker; Karl Hubner; Michael G Stabin; George Zubal; Marc Kachelriess; Valerie Cronin; Scott Holbrook
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

3.  Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies.

Authors:  Linda M Velasquez; Ronald Boellaard; Georgia Kollia; Wendy Hayes; Otto S Hoekstra; Adriaan A Lammertsma; Susan M Galbraith
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

4.  Time-of-flight positron emission tomography: status relative to conventional PET.

Authors:  T F Budinger
Journal:  J Nucl Med       Date:  1983-01       Impact factor: 10.057

5.  Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.

Authors:  Kenichiro Hamada; Yasuhiko Tomita; Takafumi Ueda; Keisuke Enomoto; Shigeki Kakunaga; Akira Myoui; Ichiro Higuchi; Hideki Yoshikawa; Jun Hatazawa
Journal:  Ann Nucl Med       Date:  2006-12       Impact factor: 2.668

6.  An assessment of the impact of incorporating time-of-flight information into clinical PET/CT imaging.

Authors:  Cristina Lois; Bjoern W Jakoby; Misty J Long; Karl F Hubner; David W Barker; Michael E Casey; Maurizio Conti; Vladimir Y Panin; Dan J Kadrmas; David W Townsend
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

7.  The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man.

Authors:  S C Jones; A Alavi; D Christman; I Montanez; A P Wolf; M Reivich
Journal:  J Nucl Med       Date:  1982-07       Impact factor: 10.057

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  Quantitative comparison of PET performance-Siemens Biograph mCT and mMR.

Authors:  Anna M Karlberg; Oddbjørn Sæther; Live Eikenes; Pål Erik Goa
Journal:  EJNMMI Phys       Date:  2016-02-25

10.  Improvement in PET/CT image quality in overweight patients with PSF and TOF.

Authors:  Takafumi Taniguchi; Go Akamatsu; Yukiko Kasahara; Katsuhiko Mitsumoto; Shingo Baba; Yuji Tsutsui; Kazuhiko Himuro; Shohei Mikasa; Daisuke Kidera; Masayuki Sasaki
Journal:  Ann Nucl Med       Date:  2014-09-26       Impact factor: 2.668

View more
  5 in total

1.  First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Authors:  Gary A Ulaner; Serge K Lyashchenko; Christopher Riedl; Shutian Ruan; Pat B Zanzonico; Diana Lake; Komal Jhaveri; Brian Zeglis; Jason S Lewis; Joseph A O'Donoghue
Journal:  J Nucl Med       Date:  2017-11-16       Impact factor: 10.057

2.  Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm.

Authors:  Youngho Seo; Mohammad Mehdi Khalighi; Kristen A Wangerin; Timothy W Deller; Yung-Hua Wang; Salma Jivan; Maureen P Kohi; Rahul Aggarwal; Robert R Flavell; Spencer C Behr; Michael J Evans
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

3.  Validation of Deep Learning-based Augmentation for Reduced 18F-FDG Dose for PET/MRI in Children and Young Adults with Lymphoma.

Authors:  Ashok J Theruvath; Florian Siedek; Ketan Yerneni; Anne M Muehe; Sheri L Spunt; Allison Pribnow; Michael Moseley; Ying Lu; Qian Zhao; Praveen Gulaka; Akshay Chaudhari; Heike E Daldrup-Link
Journal:  Radiol Artif Intell       Date:  2021-10-06

4.  Investigating Low-Dose Image Quality in Whole-Body Pediatric 18F-FDG Scans Using Time-of-Flight PET/MRI.

Authors:  Jeffrey P Schmall; Suleman Surti; Hansel J Otero; Sabah Servaes; Joel S Karp; Lisa J States
Journal:  J Nucl Med       Date:  2020-06-01       Impact factor: 11.082

5.  Phantom-based image quality assessment of clinical 18F-FDG protocols in digital PET/CT and comparison to conventional PMT-based PET/CT.

Authors:  Silvano Gnesin; Christine Kieffer; Konstantinos Zeimpekis; Jean-Pierre Papazyan; Renaud Guignard; John O Prior; Francis R Verdun; Thiago V M Lima
Journal:  EJNMMI Phys       Date:  2020-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.